199 related articles for article (PubMed ID: 2196987)
1. N-myc oncogene and stage IV-S neuroblastoma. Preliminary observations on ten cases.
Nakagawara A; Sasazuki T; Akiyama H; Kawakami K; Kuwano A; Yokoyama T; Kume K
Cancer; 1990 May; 65(9):1960-7. PubMed ID: 2196987
[TBL] [Abstract][Full Text] [Related]
2. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
3. [Amplification of the N-myc cellular oncogene in neuroblastoma. Relation to other tumor markers].
Verdona G; Garaventa A; Coviello DA; Cornaglia-Ferraris P; Tonini GP
Boll Ist Sieroter Milan; 1986; 65(4):304-8. PubMed ID: 3790277
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of oncogene activation in human neuroblastomas.
Brodeur GM; Seeger RC; Sather H; Dalton A; Siegel SE; Wong KY; Hammond D
Cancer; 1986 Jul; 58(2 Suppl):541-5. PubMed ID: 3719548
[TBL] [Abstract][Full Text] [Related]
5. Surgical aspects of N-myc oncogene amplification of neuroblastoma.
Nakagawara A; Ikeda K; Yokoyama T; Tsuda T; Higashi K
Surgery; 1988 Jul; 104(1):34-40. PubMed ID: 3388178
[TBL] [Abstract][Full Text] [Related]
6. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
Seeger RC; Brodeur GM; Sather H; Dalton A; Siegel SE; Wong KY; Hammond D
N Engl J Med; 1985 Oct; 313(18):1111-6. PubMed ID: 4047115
[TBL] [Abstract][Full Text] [Related]
7. N-myc oncogene expression and amplification in metastatic lesions of stage IV-S neuroblastoma.
Garvin J; Bendit I; Nisen PD
Cancer; 1990 Jun; 65(11):2572-5. PubMed ID: 1692506
[TBL] [Abstract][Full Text] [Related]
8. [N-myc gene copies in children with neuroblastoma and its clinical significance].
Ma XL; Gong LP; Zhou CJ; Zhang DW; Jin M; Wang HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1447-51. PubMed ID: 23257451
[TBL] [Abstract][Full Text] [Related]
9. Amplification of N-myc oncogene in stage II and IVS neuroblastomas may be a prognostic indicator.
Nakagawara A; Ikeda K; Tsuda T; Higashi K; Okabe T
J Pediatr Surg; 1987 May; 22(5):415-8. PubMed ID: 3585663
[TBL] [Abstract][Full Text] [Related]
10. Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas.
Tsuda T; Obara M; Hirano H; Gotoh S; Kubomura S; Higashi K; Kuroiwa A; Nakagawara A; Nagahara N; Shimizu K
Cancer; 1987 Aug; 60(4):820-6. PubMed ID: 3594401
[TBL] [Abstract][Full Text] [Related]
11. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
12. N-myc oncogene and urinary catecholamines in children with neuroblastoma.
Barontini M; Gutiérrez MI; Levin G; Mur N; Diez B
Med Pediatr Oncol; 1993; 21(7):499-504. PubMed ID: 8341218
[TBL] [Abstract][Full Text] [Related]
13. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma.
Bourhis J; De Vathaire F; Wilson GD; Hartmann O; Terrier-Lacombe MJ; Boccon-Gibod L; McNally NJ; Lemerle J; Riou G; Bénard J
Cancer Res; 1991 Jan; 51(1):33-6. PubMed ID: 1988094
[TBL] [Abstract][Full Text] [Related]
14. [Sensibility and specificity of N-myc oncogene with respect to other prognostic factors in 15 neuroblastomas].
Queizán A; García-Miguel P; Belló MJ; Castresana JC; Rey JA; Pestaña A
Cir Pediatr; 1995 Jul; 8(3):96-8. PubMed ID: 8527322
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
[TBL] [Abstract][Full Text] [Related]
16. Amplification of N-myc gene and increase of urinary VMA and HVA in patients with neuroblastic tumors.
Akimaru K; Shoji T; Fukunaga Y; Yamamoto M; Ishizaki R; Nomura N
Nihon Ika Daigaku Zasshi; 1994 Apr; 61(2):148-53. PubMed ID: 8195324
[TBL] [Abstract][Full Text] [Related]
17. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
18. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas.
Suzuki T; Bogenmann E; Shimada H; Stram D; Seeger RC
J Natl Cancer Inst; 1993 Mar; 85(5):377-84. PubMed ID: 8433391
[TBL] [Abstract][Full Text] [Related]
19. N-myc oncogene amplification and prognostic factors of neuroblastoma in children.
Nakagawara A; Ikeda K; Tsuda T; Higashi K
J Pediatr Surg; 1987 Oct; 22(10):895-8. PubMed ID: 3316592
[TBL] [Abstract][Full Text] [Related]
20. N-myc oncogene RNA expression in neuroblastoma.
Nisen PD; Waber PG; Rich MA; Pierce S; Garvin JR; Gilbert F; Lanzkowsky P
J Natl Cancer Inst; 1988 Dec; 80(20):1633-7. PubMed ID: 2461451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]